This is a U.S. news story, published by Yahoo, that relates primarily to Eli Lilly's news.
For more U.S. news, you can click here:
more U.S. newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
blockbuster diabetes drug. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug regulator news, clinical trial news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
popular obesity treatmentReuters
•77% Informative
U.S. drugmaker Eli Lilly's Mounjaro is a blockbuster diabetes drug and a wildly popular obesity treatment.
India has the world's second -highest number of people with type 2 diabetes and high obesity rates.
The global weight-loss drugs market is estimated to reach at least $100 billion by the decade's end .
VR Score
89
Informative language
98
Neutral language
23
Article tone
formal
Language
English
Language complexity
63
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links